Orindille (Drospirenone, Ethinylestradiol)

Drospirenone acts as a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic properties. In combination with ethinylestradiol, it suppresses the hypothalamic‑pituitary‑gonadal axis, preventing the luteinizing hormone surge, inhibiting ovulation, thickening cervical mucus and altering the endometrium to reduce the chance of implantation.

The dosing regimen for Orindille is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any break periods are set by the prescriber based on individual patient needs.

Orindille is contraindicated during pregnancy; it should be discontinued immediately if pregnancy is confirmed. While limited data exist for breastfeeding, the product is generally not recommended unless the benefits outweigh potential risks, and a healthcare provider should be consulted.

To order Orindille, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Orindille contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic activity, potentially providing benefits such as reduced water retention and improved acne control compared with some older progestins. Efficacy in preventing pregnancy is comparable to other combined oral contraceptives when taken correctly.

Orindille tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Orindille is taken orally, usually as a single tablet each day. It is important to take the tablet at roughly the same time each day to maintain consistent hormone levels and maximize contraceptive effectiveness.

The most serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, and hypertensive crises. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Orindille should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic events, uncontrolled hypertension, severe liver disease, or who are smokers over 35 years of age. Consultation with a healthcare professional is essential to assess suitability.